Biomoda’s CyPath Assay Statistically Significant as Evidenced by Pilot Study Results

Biomoda (OTCBB: BMOD) released top line results for its pilot study for lung cancer and we are pleased with what we saw.  In short, the study provides evidence to conclude that the Company’s biomarker assay, CyPath, can discriminate between cancer and non-cancer groups based on sputum samples collected in a non-invasive manner. 

The key to cancer survival, whether it is lung cancer or any other form of cancer, is early detection.  And based on results from this study, Biomoda is able to identify and quantify cellular characteristics that differ between groups of individuals at high risk for developing cancer and those who already have the disease.  At this point, this is exactly what the Company was hoping for.  Going forward there are certain areas which can be improved, but that is really just tweaking that which we know works. 

Congrats to the Biomoda team for a job well done.  We look forward to continued success from the Company.

Read More

One Response to Biomoda’s CyPath Assay Statistically Significant as Evidenced by Pilot Study Results

  1. Bill says:

    What happened today?

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: